Tonix Pharma Announces Licensing Exclusive Worldwide Rights To TNX-4900, Small-Molecule S1R Antagonist With Demonstrated Analgesic Activity In Multiple Models Of Neuropathic Pain

Benzinga · 1d ago

Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic pain

Compelling safety and pharmacokinetic profiles in animals support IND-enabling studies

CHATHAM, N.J., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated commercial biotechnology company, today announced licensing exclusive worldwide rights to TNX-4900 (formerly known as PW507), a highly selective small-molecule Sigma-1 receptor (S1R) antagonist with demonstrated analgesic activity in multiple models of neuropathic pain.